Skip to main content

ASCO GU 2023 Highlights

In his keynote address at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium, Norman E. “Ned” Sharpless, MD, Former Director of the National Cancer Institute (NCI), and Professor, Cancer Policy and Innovation, University of North Carolina School of Medicine, Chapel Hill, told attendees that although cancer-related mortality is declining, challenges remain to “end cancer as we know it.” Read More ›

An analysis from the ARASENS trial showed that the addition of darolutamide (Nubeqa) to androgen-deprivation therapy (ADT) and docetaxel significantly improved overall survival (OS) in subgroups of patients with metastatic hormone-sensitive prostate cancer (mHSPC) with high-volume and high-risk disease and should be considered the new standard of care for this patient population. Read More ›